Home Pharma China Web Edition Pharma China Archives Online Databases Subscription/Order/Info Event Calendar China Pharma Providers About Us
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Featured News
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor´s Picks
 
 
 
Is China Spring Finally Here for Innovative Drugs of MNCs?
Chief Editor James Shen offers his regular monthly review of the Chinese healthcare sector with this issue's emphasis on CFDA's proposal to liberalize foreign new drug re... (3/31/2017)
   
China's Healthcare Reforms: Double-Edged Sword For The Pharmaceutical Industry (4/25/2017)
Generic Consistency Evaluation in China: The Coming Paradigm Shift In Drug Pricing And Patent Cliff (4/20/2017)
The Pulse of China's Healthcare (4/19/2017)
Traditional Chinese Medicine? 100% Made In Japan (4/18/2017)
Staffing for China's Rapidly Growing Biomanufacturing Industry (4/18/2017)
China's Push on Innovation Nourishes Cross-Border Collaborations (4/18/2017)
New Guidelines to Make China a More Drug-Friendly Market (4/3/2017)
Novartis CEO: Why China Is a Healthy Investment (4/3/2017)
Is China Spring Finally Here for Innovative Drugs of MNCs? (3/31/2017)
Maybe Multinational Pharma Shouldn't Be Scared of the Chinese Government (3/30/2017)
Global Drugmakers Poised for Windfall of Approvals in China (3/29/2017)
SIPO Amends Its Patent Examination Guidelines (3/28/2017)
Ben Shobert Testifies at U.S.-China Economic and Security Review Commission Hearing on China’s Biotech Pursuit (3/27/2017)
China's Drugmakers Need a Panacea (3/17/2017)
A Better Pill from China - Chinese Pharma Firms Target the Global Market (3/17/2017)
Non-Small Cell Lung Cancer Therapeutics ...  (4/26/2017) (free)
MIIT Reports Chinese Pharmaceutical Indu...  (4/26/2017)
Hospital Drug Sales Champions in 22 Chin...  (4/26/2017)
Hospital Drug Sales Champions in 22 Chin...  (4/26/2017)
Performance Snapshot of Leading Regional...  (4/26/2017)
Fresenius Steps Up Pharma M&A wi...  (4/25/2017)
EpimAb Bio Raises $25M to Advance Pipeli...  (4/25/2017) (free)
Zai Lab Licenses China Rights of Paratek...  (4/25/2017)
Gilead to Build Its First Overseas Manuf...  (4/25/2017)
Chongqing Becomes the First to Offer Pre...  (4/24/2017)
HitGen Announces Drug Discovery Collabor...  (4/24/2017)
CDE to Hire Part Time Clinical Reviewers...  (4/24/2017)
BeiGene Announces Initiation of First Pi...  (4/21/2017)
Seven Central Government Agencies Issue ...  (4/21/2017)
Domestically-listed Pharma Companies Rep...  (4/20/2017)
Fresenius Steps Up Pharma M&A with Akorn, Merck ...
Global Pharmerging Market to Grow at a CAGR of 12.88% in...
PhRMA Urges USTR to Protect US Innovation Abroad
Trump Wants Big Pharma Cut Outsourcing and Prices, Promi...
Mergermarket: Global Pharma and Biotech M&A Feels th...
Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets...
Hospital Drug Sales Champions in 22 Chinese Cities/Regions
Hospital Drug Sales Champions in 22 Chinese Cities/Regions
CPIIC: Overview of Urban Hospital Drug Consumption in 2016
Review and Prospects of Chinese Vaccine Market
MIIT Reports Chinese Pharmaceutical Industry Performance in ...
Performance Snapshot of Leading Regional Pharmaceutical Dist...
EpimAb Bio Raises $25M to Advance Pipeline of Novel Bispecif...
Zai Lab Licenses China Rights of Paratek's Late-Stage Antibi...
Gilead to Build Its First Overseas Manufacturing Facility in...
CDE Solicits Comments on Draft Technical Guidelines for ...
11 Central Agencies Issue Notice over Publication of Maj...
CDE Publicizes List of Drug Applications To Be Granted P...
CDE Solicits Public Comments on Six TCM Technical Guidel...
CFDA Issues New Announcement (2017#42) for Clinical Data...
PhRMA Criticizes China Over Failure to Uphold Data Exclusivi...
China to Introduce Interpretations for Application of Crimin...
Shenzhen Makes Corrections after NDRC Finds the City's GPO R...
U.S. Charges Two Chinese Healthcare Executives with $400M Fr...
SIPO: Chinese Patent Applications Grew 23.8% in 2016
U.S. FDA Raises Concerns over Teva's Plant In China
U.S. FDA Warns Jinda Pharma for Data Integrity Violation...
USFDA Warns Lumis Global Pharma of cGMP Deficiencies
U.S. FDA Issues Warning to Fosun's API Subsidiary over D...
India Pressures CFDA to Act and Restore Supply of Rare D...
BeiGene Announces Initiation of First Pivotal Study in C...
CFDA Approves JHL's IND for Clinical Trial of Rituximab ...
Chi-Med Announces Positive Phase III Results of Colorect...
Luye Pharma Obtains Clinical Trials Approval for Rivasti...
BeiGene Initiates First Pivotal Study in China with BTK ...
Chongqing Becomes the First to Offer Preference to Drugs...
Seven Central Government Agencies Issue Joint Notice to ...
Post-SARS, Infection Rates in China Steadied But Rising ...
State Council Lays Out Major Healthcare Reform Tasks in ...
MOHRSS Seeks Suggestions on Dynamic Revision Mechanism o...
CDE to Hire Part Time Clinical Reviewers
Recent Executive Moves
Recent Executive Moves
32 Chinese Pharma Billionaires on 2016 Forbes Rich List
Recent Executive Moves
Upcoming Event: Pharma China Annual Forum 2017 in Shangh...
Upcoming Event: MEDEXPO AFRICA 2017
Upcoming Event: Pharma China Annual Forum 2017 in Shangh...
Upcoming Event: Pharma China Annual Forum 2017 in Shangh...
Upcoming Event: Negotiation with International Healthcar...
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
  WiCON Officially Publishes Chi...
  WiCON and PharmaGuys Launch Ph...
  WiCON Officially Publishes Chi...
  WiCON Officially Publishes Its...
  WiCON Publishes China Pharmace...
© Wicon International Group  Support by: www.heightow.com Site map | Contact Us | Links